

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## 东曜药业

### TOT BIOPHARM International Company Limited

#### 東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

### VOLUNTARY ANNOUNCEMENT

#### ENTERING INTO OF AN EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH A WHOLLY-OWNED SUBSIDIARY OF JIMIN KEXIN PHARMACEUTICAL IN RESPECT OF 朴欣汀® (BEVACIZUMAB INJECTION, PUSINTIN®) FOR THE MAINLAND CHINA MARKET

This announcement is made by TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that TOT BIOPHARM Co., Ltd. (東曜藥業有限公司) (“**TOT Suzhou**”), a wholly-owned subsidiary of the Company, has entered into an exclusive promotion service agreement (the “**Agreement**”) with Jiangxi Jixin Pharmaceutical Co., Ltd. (江西濟鑫醫藥有限公司) (as the promotion service provider, “**Jixin Pharmaceutical**”), a wholly-owned subsidiary of Jiangxi Jimin Kexin Pharmaceutical Industry Investment Co., Ltd. (江西濟民可信醫藥產業投資有限公司) (“**Jimin Kexin Pharmaceutical**”), in respect of the marketing of 朴欣汀® (bevacizumab injection, intended English trade name: Pusintin®, the “**Product**”) in mainland China (i.e., excluding Hong Kong, Macau and Taiwan regions) (the “**Promotion Service Area**”), pursuant to which Jixin Pharmaceutical will enjoy the exclusive promotion right in respect of the Product in the Promotion Service Area, while TOT Suzhou will continue to possess all the rights and interests in respect of the Product in the Promotion Service Area other than promotion right.

Pursuant to the Agreement, TOT Suzhou will grant the exclusive promotion right in respect of the Product in the Promotion Service Area to Jixin Pharmaceutical. On the basis of complying with the provisions of the Agreement, Jixin Pharmaceutical and its designated related party(ies) shall be entitled to use the trademark(s) of the Product to provide exclusive promotion services in respect of the Product in the Promotion Service Area.

The entering into of the Agreement aims to quickly introduce the Product to the market through the close collaboration between TOT Suzhou and Jixin Pharmaceutical, thereby providing a high-quality drug for the benefit of Chinese patients. The Group has collaborated favorably with Jimin Kexin Pharmaceutical and its subsidiaries in the fields of product marketing and CDMO business. The entering into of the Agreement will be conducive to enhancing the brand influence of the Product and will give impetus to its marketing.

## **ABOUT 朴欣汀®**

朴欣汀® (bevacizumab injection, intended English trade name: Pusintin®) is a biological antibody drug self-developed by TOT Suzhou, which has obtained the marketing approval from the National Medical Products Administration of China recently and is used for the treatment of advanced, metastatic or recurrent non-squamous non-small-cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC). 朴欣汀® is a biosimilar to 安維汀® (Avastin®), which has been approved for the treatment of nsNSCLC, mCRC, glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), ovarian cancer and cervical cancer in China. The monoclonal antibody commercial production of 朴欣汀® is carried out by adopting the Perfusion-Batch Hybrid Technology (PB-Hybrid® Technology) self-developed by the Group, which enables seed expansion in 25L WAVE bioreactors and a direct scale-up to 2,000L bioreactors. As compared with commonly-used technologies in the industry, this technology has obvious cost advantages in terms of simplified technical processes, shortened production cycles and reduced production costs.

## **ABOUT TOT SUZHOU**

TOT Suzhou, a wholly-owned subsidiary of the Company, is dedicated to the development and commercial production of innovative oncology drugs and therapies. It has a large-scale production base for the commercialization of biological drugs that complies with international standards. By the first half of 2022, its production capacity of monoclonal antibody drugs is expected to reach 20,000L, which will ensure the high-quality production and stable market supply of 朴欣汀®.

## ABOUT JIXIN PHARMACEUTICAL

Jixin Pharmaceutical is a wholly-owned subsidiary of Jimin Kexin Pharmaceutical, while Jimin Kexin Pharmaceutical and Jiangxi Jemincare Group Co., Ltd. (江西濟民可信集團有限公司) (“**Jemincare Group**”) are controlled by the same actual controller. Founded in 1999, Jemincare Group is a renowned conglomerate in China with a focus on the modern concept of universal health. Jixin Pharmaceutical is principally engaged in the sales of pharmaceutical products domestically and internationally, with a sales network spanning nationwide and overseas thanks to the strong support from Jimin Kexin Pharmaceutical and Jemincare Group in the pharmaceutical industry.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 21 December 2021

*As at the date of this announcement, the executive directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.*